| Treatment/control group (baseline) | Difference (95% CI, P value) (baseline) | Treatment/control group (week 2) | Difference (95% CI, P value*) (week 2) | Treatment/control group (week 4) | Difference (95% CI, P value*) (week 4) | Treatment/control group (week 8) | Difference (95% CI, P value*) (week 8) |
---|---|---|---|---|---|---|---|---|
WOMAC Total score | 54.5 (10.8)/57.7 (9.7) |  − 3.2 (− 8.1 to 1.8; 0.20) | 41.9 (13.5) 48.3 (13.6) |  − 6.4 (− 12.9 to 0.12; 0.05) | 37.0 (16.2)/42.1 (16.3) |  − 5.1 (− 12.9 to 2.7; 0.20) | 31.8 (17.3)/39.9 (17.1) |  − 8.2 (− 16.5 to 0.1; 0.05) |
Pain subscale | 11.9 (2.9)/12.3 (2.9) |  − 0.41 (− 1.8 to 1.0; 0.57) | 9.0 (3.1) 10.3 (3.4) |  − 1.2 (− 2.8 to 0.34; 0.12) | 7.5 (3.6)/9.0 (3.5) |  − 1.5 (− 3.2 to 0.24; 0.09) | 6.8 (3.6)/8.6 (3.6) |  − 1.8 (− 3.5 to − 0.02; 0.048)* |
Stiffness subscale | 3.9 (1.3)/4.6 (0.9) |  − 0.7 (− 1.3 to − 0.2; 0.013)* | 3.0 (1.5) 3.7 (1.4) |  − 0.7 (− 1.4 to − 0.05; 0.035)* | 2.8 (1.5)/3.4 (1.4) |  − 0.6 (− 1.3 to 0.08; 0.082) | 2.4 (1.4)/3.4 (1.5) |  − 1.0 (− 1.6 to − 0.3; 0.008)* |
Physical function subscale | 38.7 (7.9)/40.7 (7.1) |  − 2.1 (− 5.7 to 1.6; 0.26) | 29.9 (9.9) 34.3 (10.1) |  − 4.4 (− 9.2 to 0.41; 0.07) | 26.7 (11.8)/29.7 (12.2) |  − 3.0 (− 8.8 to 2.8; 0.31) | 22.6 (12.8)/28.0 (12.6) |  − 5.5 (− 11.6 to 0.65; 0.08) |
EQ-5D Index value | 0.30 (0.29)/0.19 (0.27) | 0.10 (− 0.03 to 0.24; 0.12) | 0.47 (0.26) 0.30 (0.33) | 0.17 (0.02 to 0.31; 0.022)* | 0.51 (0.26)/0.38 (0.34) | 0.13 (− 0.01 to 0.28; 0.07) | 0.57 (0.30)/0.45 (0.29) | 0.11 (− 0.03 to 0.25; 0.13) |
EQ VAS | 54.7 (16.6)/51.8 (19.1) | 3.1 (− 5.5 to 11.7; 0.48) | 62.6 (19.3) 59.1 (16.2) | 3.5 (− 5.12 to 12.0; 0.42) | 65.9 (14.0)/62.1 (18.6) | 3.8 (− 4.1 to 11.7; 0.34) | 65.7 (19.2)/62.9 (16.5) | 2.9 (− 5.8 to 11.5; 0.51) |